Navigation Links
Heartware Schedules First Quarter Conference Call And Webcast
Date:5/3/2012

FRAMINGHAM, Mass. and SYDNEY, May 3, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2012, at 5:00 p.m. U.S. Eastern Daylight Time on Thursday, May 10, 2012 (being 7:00 a.m. Australian Eastern Standard Time, on May 11, 2012). The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the quarter and business outlook.  The call may be accessed by dialing 1-888-549-7704 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9810.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare First Quarter 2012 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's website, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  The HeartWare System has received CE Marking in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: destination therapy and bridge-to-transplant under a continued access protocol.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. HeartWare Receives 54-Patient Allotment From FDA Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
3. HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
4. HeartWare Schedules Fourth Quarter Conference Call and Webcast
5. HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
6. HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
8. HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
9. HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
10. HeartWare International Announces Planned Departure of Chief Financial Officer
11. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... India , May 4, 2016 ... spreads across 154 pages, profiling 09 key companies ... is a professional and in-depth study on the ... a basic overview of the industry including definitions, ... Needles market analysis is provided for the international ...
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... 4, 2016 Research and Markets ... Stem Cell Therapy Market Outlook 2020" report to ... ) , ,Recombinant technology has improved significantly in past ... be developed in coming years. Many cancer drugs have ... cell therapies are also expected to be developed with ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Sandbox, one of the ... serve in the newly created position of executive vice president, chief creative officer.     ... in the Chicago and LA offices. He reports to Nancy Finigan, president of ...
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved walking ... her with one on her shoulder and one on her arm. But she got ... of years of mitral valve prolapse. , The valves of the heart wouldn’t close ...
(Date:5/3/2016)... ... 03, 2016 , ... Excessive panting in the car or cowering when new ... often think anxiety only manifests itself as trembling or ‘tail between the legs,’ but ... that be done about it,” says Dr. Jim Lowe, technical services veterinarian for Tomlyn ...
(Date:5/3/2016)... ... 2016 , ... Diagnotes, a leader in digital healthcare communications, ... system in South Carolina, to provide its secure mobile communication platform. , “Healthcare ... drives workflow efficiencies and improves provider and patient satisfaction,” said Dr. Todd Rowland, ...
(Date:5/3/2016)... ... 2016 , ... Boston Children’s Hospital today announced its new pediatric Simulation (SIM) ... or rare procedures in an environment that looks and feels real. , Located in ... inventors and “hackers” to develop and test new devices or software platforms and see ...
Breaking Medicine News(10 mins):